1. Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.
- Author
-
Packer M
- Subjects
- Benzhydryl Compounds pharmacology, Benzhydryl Compounds therapeutic use, Blood Volume drug effects, Death, Sudden, Cardiac etiology, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 physiopathology, Diabetic Cardiomyopathies complications, Diabetic Cardiomyopathies physiopathology, Diuretics therapeutic use, Glucose metabolism, Glucosides pharmacology, Glucosides therapeutic use, Heart Failure etiology, Heart Failure physiopathology, Hospitalization statistics & numerical data, Humans, Hypoglycemic Agents therapeutic use, Kidney Tubules, Proximal drug effects, Kidney Tubules, Proximal metabolism, Multicenter Studies as Topic, Myocardial Infarction etiology, Myocardial Infarction prevention & control, Natriuresis drug effects, Randomized Controlled Trials as Topic, Sodium-Glucose Transporter 2 physiology, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Stroke etiology, Stroke prevention & control, Stroke Volume drug effects, Death, Sudden, Cardiac prevention & control, Diabetes Mellitus, Type 2 drug therapy, Heart Failure drug therapy, Hypoglycemic Agents pharmacology, Sodium-Glucose Transporter 2 Inhibitors pharmacology, Sodium-Hydrogen Exchanger 1 antagonists & inhibitors
- Published
- 2019
- Full Text
- View/download PDF